Trial Profile
A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PRIDE
- Sponsors Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- 25 Sep 2023 Results of post hoc pooled analysis of NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM) assessing the efficacy and safety of paliperidone palmitate (PP) versus oral antipsychotic (OAP) treatment in adult patients diagnosed with schizophrenia (per DSM IV or DSM 5 criteria) and varying duration of illness (o to 3 years and greater than 3 years) published in the Journal of clinical psychiatry, 2023.
- 03 Jan 2018 Results presented in a Johnson & Johnson Media Release.
- 03 Jan 2018 According to a Janssen Pharmaceuticals media release, the U.S. FDA approved the inclusion of real-world data from this study in the INVEGA SUSTENNA label.